Equity Profile

CRL

Charles River Laboratories International, Inc.

Health CareLife Sciences Tools & Services$13.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Charles River Laboratories International, Inc. (CRL) is a key player in the health care sector, providing essential services and tools for life sciences research....

Key Metrics to Watch

EPS

Earnings per share is a primary indicator of profitability and is closely watched by investors.

$2.74

Revenue

Revenue figures provide insight into the company's sales performance and overall growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Charles River Laboratories International, Inc. (CRL) is a key player in the health care sector, providing essential services and tools for life sciences research. The company supports pharmaceutical and biotechnology companies in developing new drugs and therapies, making it crucial for advancements in health care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1-2026, CRL reported an EPS of $2.06, exceeding expectations by 5.21%. However, the stock saw a slight decline of 0.03% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect CRL to continue its trend of beating earnings estimates, with a consensus EPS of $2.74 for Q2-2026. The market is cautiously optimistic given the company's history of positive surprises.

Bull Case

If CRL meets or exceeds the EPS estimate, it could signal strong operational performance and continued demand for its services, potentially leading to a positive stock reaction.

Bear Case

Conversely, if CRL fails to meet expectations, it may raise concerns about demand in the life sciences sector, leading to a negative impact on the stock.

Key Metrics to Watch

EPS

$2.74

Earnings per share is a primary indicator of profitability and is closely watched by investors.

Revenue

$977M

Revenue figures provide insight into the company's sales performance and overall growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRL's EPS exceed the consensus estimate of $2.74?

A beat on EPS would reinforce the company's strong performance and could drive positive investor sentiment.

What are the revenue figures and growth outlook for the life sciences segment?

Understanding revenue growth will provide insights into demand trends and the company's market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRL's ability to capitalize on increasing demand for life sciences tools, especially given recent industry trends.

Supporting Evidence

CRL has consistently exceeded EPS expectations in the past, indicating strong operational capabilities.

The options market is pricing in a larger move than historical averages, suggesting that investors are anticipating significant news.

Key Risk

If revenue growth falls below the expected $977M, it could challenge the positive outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether CRL can maintain its growth trajectory in a competitive market.

Bull Confirmed If

An EPS of $2.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.68 would raise concerns about demand and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests a potential stock increase of around 1.27%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 0% based on past reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends in the life sciences sector.
2Details on new contracts or partnerships that may impact future revenue.
3Management's commentary on cost management and operational efficiencies.
4Insights into competitive pressures and how CRL plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Charles River Laboratories International, Inc. (CRL) is a key player in the health care sector, providing essential services and tools for life sciences research....

Key Metrics to Watch

EPS

Earnings per share is a primary indicator of profitability and is closely watched by investors.

$2.74

Revenue

Revenue figures provide insight into the company's sales performance and overall growth.

$977M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.31%

Avg Stock Reaction

+1.27%

Last Quarter Recap

In Q1-2026, CRL reported an EPS of $2.06, exceeding expectations by 5.21%. However, the stock saw a slight decline of 0.03% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If CRL meets or exceeds the EPS estimate, it could signal strong operational performance and continued demand for its services, potentially leading to a positive stock reaction.

Bear Case

Conversely, if CRL fails to meet expectations, it may raise concerns about demand in the life sciences sector, leading to a negative impact on the stock.

Key Metrics to Watch

EPS

$2.74

Earnings per share is a primary indicator of profitability and is closely watched by investors.

Revenue

$977M

Revenue figures provide insight into the company's sales performance and overall growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRL's EPS exceed the consensus estimate of $2.74?

A beat on EPS would reinforce the company's strong performance and could drive positive investor sentiment.

What are the revenue figures and growth outlook for the life sciences segment?

Understanding revenue growth will provide insights into demand trends and the company's market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CRL's ability to capitalize on increasing demand for life sciences tools, especially given recent industry trends.

Supporting Evidence

CRL has consistently exceeded EPS expectations in the past, indicating strong operational capabilities.

The options market is pricing in a larger move than historical averages, suggesting that investors are anticipating significant news.

Key Risk

If revenue growth falls below the expected $977M, it could challenge the positive outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether CRL can maintain its growth trajectory in a competitive market.

Bull Confirmed If

An EPS of $2.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.68 would raise concerns about demand and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.01%

Historical Avg

±8.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±10.0% while CRL has averaged ±8.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.1%

Calls (154K)P/C Ratio: 1.46Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRL beats expectations, history suggests a potential stock increase of around 1.27%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 0% based on past reactions.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends in the life sciences sector.
2Details on new contracts or partnerships that may impact future revenue.
3Management's commentary on cost management and operational efficiencies.
4Insights into competitive pressures and how CRL plans to address them.